Delivery Order SPE2DB22D1103-SPE2DB25FTLB6
- Not listed
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count units) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by June 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $1,768.44 delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed price contract type. The award was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,874.46 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed-price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,877.45 delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) on June 16, 2025, with a completion date of June 17, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,794.10 to AmerisourceBergen Drug Corp for XCOPRI 150 mg tablets (30-count supply) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running...
- The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count package). The contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) on July 18, 2025, with a ceiling value of $1,323.89 and an ultimate completion date of July 21, 2025. This is a firm fixed price, non-competitive delivery order with no set-aside designation. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 MG tablets (30-count units) with a firm fixed price contract type. This delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 25, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This award represents a child delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count package) valued at $1,277.60 under a firm fixed-price contract type. The award was made on September 12, 2025, with an ultimate completion date of September 15, 2025. This delivery order is non-set-aside and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract, consistent with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-count) on May 20, 2025, with a ceiling value of $1,979.46 under a firm fixed-price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made through open competition with no set-aside designation,...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTLB6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count) with a ceiling value of $1,786.08. This firm fixed-price delivery order, issued on April 24, 2025, with a completion date of April 25, 2025, was competitively awarded without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal medical procurement vendor serving Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of delivery orders with DLA covering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This particular order for XCOPRI, a neurological medication, exemplifies the company's role in supplying specialized pharmaceuticals to support military and federal healthcare operations through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 4/24/25 |